Foreign Corrupt Practices Act (FCPA): How 2011 Enforcement Initiatives Will Affect Your Company

December 7, 2010

Since November of 2009, the Department of Justice (DOJ) has moved forward with its industry-wide pharmaceutical and medical device FCPA initiative.  The DOJ and the FBI's Washington Field Office (WFO) are taking aggressive action across the industries to enforce the FCPA's anti-bribery provisions.  With over twenty pharmaceutical and device companies being investigated for violating the FCPA's anti-bribery provisions, companies need to align global compliance programs and leverage their experience dealing with DOJ matters in developing integrated strategies for responding to FCPA inquiries.

Meet the Speakers

Kirk Ogrosky
Arnold & Porter
John N. Nassikas
Arnold & Porter
Subscribe Link

Email Disclaimer